help me understand rodent data, I have read the wiki twice
help me understand rodent data, I have read the wiki twice. If this has been answered properly somewhere, link me and I will delete.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Sent a vial to VendorInvestigate: 97.7% against a claimed 97.0%, with the mass confirming the sequence. Both halves mattered to me.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Which paper is that claim from, and was it in humans?
no clinical trial has established what these threads assert
pentadecapeptide, fifteen residues, and the sequence is public
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.
Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Citation requested rather than removal. A claim here should say whether its source is preclinical.
identity testing matters more here than purity does
Agreed. Identity is the question here. A short peptide can be synthesised by almost anyone and the sequence is what you are actually buying.
This. Mass spectrometry for identity, not just an area percent, because a pure something-else is still something else.
Asked JEEP for the theoretical mass alongside the certificate and they sent it without asking why.
Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.
- 1Ask for the theoretical mass alongside the measured one. It is a one-line…7 comments in this branch · started by u/careful_gradient
- 2Short peptides in solution are subject to hydrolysis and, depending on…7 comments in this branch · started by u/mariam_mensa